{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:53:44Z","timestamp":1780412024643,"version":"3.54.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":457,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1002\/2327-6924.12133","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T03:23:33Z","timestamp":1400037813000},"page":"330-339","source":"Crossref","is-referenced-by-count":12,"title":["Evidence-based treatment of frequent heartburn: The benefits and limitations of over-the-counter medications"],"prefix":"10.1097","volume":"26","author":[{"given":"Johnson W.","family":"McRorie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210303","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2004.00620.x","article-title":"Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn.","volume":"30","author":"Allgood","year":"2005","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"R2-8-20210303","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1365-2036.2001.01087.x","article-title":"Pharmacokinetics and pharmacodynamics of esomeprazole, the Sisomer of omeprazole.","volume":"15","author":"Andersson","year":"2001","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"4","key":"R3-8-20210303","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2036.2004.02085.x","article-title":"The role of acid suppression in patients with endoscopynegative reflux disease: The effect of treatment with esomeprazole or omeprazole.","volume":"20","author":"Armstrong","year":"2004","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R6-8-20210303","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.318.7182.502","article-title":"Symptomatic gastrooesophageal reflux disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine.","volume":"318","author":"Bardhan","year":"1999","journal-title":"British Medical Journal"},{"key":"R7-8-20210303","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","article-title":"Appropriate acid suppression for the management of gastrooesophageal reflux disease.","volume":"51","author":"Bell","year":"1992","journal-title":"Digestion"},{"key":"R8-8-20210303","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/236385a0","article-title":"Definition and antagonism of histamine H2receptors.","volume":"236","author":"Black","year":"1972","journal-title":"Nature"},{"key":"R9-8-20210303","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1046\/j.1365-2036.2002.01380.x","article-title":"Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control.","volume":"16","author":"Collings","year":"2002","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R10-8-20210303","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00045391-199506000-00007","article-title":"Comparative effect of liquid antacids on esophageal and gastric pH in subjects with heartburn.","volume":"2","author":"Decktor","year":"1995","journal-title":"American Journal of Therapeutics"},{"key":"R11-8-20210303","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00045391-199508000-00006","article-title":"Effects of aluminummagnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn.","volume":"2","author":"Decktor","year":"1995","journal-title":"American Journal of Therapeutics"},{"key":"R14-8-20210303","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/gast.2002.31876","article-title":"Longterm effect of H2RA therapy on nocturnal gastric acid breakthrough.","volume":"122","author":"Fackler","year":"2002","journal-title":"Gastroenterology"},{"key":"R15-8-20210303","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/00365520601026665","article-title":"Can famotidine and omeprazole be combined on a oncedaily basis?","volume":"42","author":"Fandriks","year":"2007","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"R16-8-20210303","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1440-1746.2006.04323.x","article-title":"Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.","volume":"21","author":"Furuta","year":"2006","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"R17-8-20210303","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/bega.2001.0190","article-title":"Problems related to acid rebound and tachyphylaxis.","volume":"15","author":"Gillen","year":"2001","journal-title":"Best Practice Research Clinical Gastroenterology"},{"key":"R18-8-20210303","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjsurg.2002.10.002","article-title":"Omeprazole is more effective than a histamine H2receptor blocker for maintaining a persistent elevation of gastric pH after colon resection for cancer.","volume":"187","author":"Hsu","year":"2004","journal-title":"American Journal of Surgery"},{"key":"R19-8-20210303","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/bega.2001.0184","article-title":"Pharmacological and pharmacodynamics essentials of H2receptor antagonists and proton pump inhibitors for the practicing physician.","volume":"15","author":"Huang","year":"2001","journal-title":"Best Practice Research Clinical Gastroenterology"},{"key":"R20-8-20210303","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2036.1994.tb00278.x","article-title":"Comparison of acid inhibition by either oral highdose ranitidine or omeprazole.","volume":"8","author":"Hurlimann","year":"1994","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R21-8-20210303","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease.","volume":"108","author":"Katz","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"R22-8-20210303","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1440-1746.2003.03041.x","article-title":"Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.","volume":"18","author":"Komazawa","year":"2003","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"R23-8-20210303","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12325-011-0013-5","article-title":"Review of proton pump inhibitors for the initial treatment of heartburn: Is there a dose ceiling effect?","volume":"28","author":"Kushner","year":"2011","journal-title":"Advances in Therapy"},{"issue":"4","key":"R24-8-20210303","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2009.07.2019","article-title":"Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: Results of 2 randomized, placebocontrolled, doubleblind studies.","volume":"121","author":"Kushner","year":"2009","journal-title":"Postgraduate Medicine"},{"key":"R25-8-20210303","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.1987.tb00623.x","article-title":"Twentyfourhour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.","volume":"1","author":"LanzonMiller","year":"1987","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"7","key":"R26-8-20210303","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2036.1999.00564.x","article-title":"On demand therapy with omeprazole for the longterm management of patients with heartburn without oesophagitisA placebocontrolled randomized trial.","volume":"13","author":"Lind","year":"1999","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"7","key":"R27-8-20210303","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2036.2000.00813.x","article-title":"Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastrooesophageal reflux disease.","volume":"14","author":"Lind","year":"2000","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R28-8-20210303","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0016-5085(93)90892-G","article-title":"Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.","volume":"105","author":"Merki","year":"1993","journal-title":"Gastroenterology"},{"key":"R29-8-20210303","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0016-5085(94)94341-9","article-title":"Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?","volume":"106","author":"Merki","year":"1994","journal-title":"Gastroenterology"},{"issue":"4","key":"R30-8-20210303","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2010.04544.x","article-title":"Intragastric acidity during administration of generic omeprazole or esomeprazoleA randomised, twoway crossover study including CYP2C19 genotyping.","volume":"33","author":"Miehlke","year":"2011","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"12","key":"R32-8-20210303","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A fiveway crossover study.","volume":"98","author":"Miner","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"R33-8-20210303","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1365-2036.2010.04258.x","article-title":"Omeprazolemg 20.6mg is superior to lansoprazole 15mg for control of gastric acid: A comparison of overthecounter doses.","volume":"31","author":"Miner","year":"2010","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R31-8-20210303","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2036.2006.03129.x","article-title":"Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.","volume":"25","author":"Miner","year":"2006","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"Suppl 1","key":"R34-8-20210303","first-page":"1","article-title":"Gastrooesophageal reflux disease: The extent of the problem.","volume":"22","author":"Moayyedi","year":"2005","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"Suppl 1","key":"R36-8-20210303","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.1990.tb00010.x","article-title":"Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine.","volume":"4","author":"Nwokolo","year":"1990","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R37-8-20210303","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1001\/archinte.159.14.1592","article-title":"Heartburn risk factors, knowledge, and prevention strategies: A populationbased survey of individuals with heartburn.","volume":"159","author":"Oliveria","year":"1999","journal-title":"Archives of Internal Medicine"},{"key":"R38-8-20210303","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1440-1746.2008.05644.x","article-title":"Immediate acidsuppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, crossover study using wireless pH monitoring capsules.","volume":"24","author":"Ono","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 4a","key":"R39-8-20210303","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.1016\/S0002-9343(99)00348-4","article-title":"Mechanisms of refluxinduced epithelial injuries in the esophagus.","volume":"108","author":"Orlando","year":"2000","journal-title":"American Journal of Medicine"},{"issue":"12","key":"R40-8-20210303","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1001\/archinte.160.12.1810","article-title":"Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.","volume":"160","author":"Richter","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"21","key":"R41-8-20210303","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/archinte.158.21.2373","article-title":"Heartburn requiring frequent antacid use may indicate significant illness.","volume":"158","author":"Robinson","year":"1998","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"R42-8-20210303","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1365-2036.2002.01178.x","article-title":"Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn.","volume":"16","author":"Robinson","year":"2002","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R43-8-20210303","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1365-2036.2004.02217.x","article-title":"A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn.","volume":"20","author":"RodriguezStanley","year":"2004","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R44-8-20210303","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1053\/j.gastro.2008.05.021","article-title":"Control of gastric acid secretion in health and disease.","volume":"134","author":"Schubert","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"R45-8-20210303","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1572-0241.2003.07531.x","article-title":"Nighttime heartburn is an underappreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association.","volume":"98","author":"Shaker","year":"2003","journal-title":"American Journal of Gastrenterology"},{"key":"R46-8-20210303","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10620-006-9490-9","article-title":"Which has superior acidsuppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylorinegative CYP2C19 extensive metabolizers.","volume":"52","author":"Shimatani","year":"2007","journal-title":"Digestive Diseases and Sciences"},{"issue":"10","key":"R47-8-20210303","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s10620-006-9643-x","article-title":"Acidsuppressive effects of various regimens of omeprazole in Helicobacter pylorinegative CYP2C19 homozygous extensive metabolizers: Which regimen has the strongest effect?","volume":"52","author":"Shimatani","year":"2007","journal-title":"Digestive Diseases and Sciences"},{"issue":"10","key":"R48-8-20210303","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3109\/00365529709011211","article-title":"Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastrooesophageal reflux disease in general practice.","volume":"32","author":"Venables","year":"1997","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"Suppl 193","key":"R49-8-20210303","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/00365529209096000","article-title":"Tolerance during dosing with H2receptor antagonists.","volume":"27","author":"WilderSmith","year":"1992","journal-title":"Scandinavian Journal of Gastroenterology"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2F2327-6924.12133","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/2327-6924.12133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T22:26:21Z","timestamp":1746224781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201406000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/2327-6924.12133","relation":{},"ISSN":["2327-6924"],"issn-type":[{"value":"2327-6924","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}